AMGN
Price
$272.05
Change
-$3.79 (-1.37%)
Updated
May 8 closing price
Capitalization
151.69B
88 days until earnings call
BMY
Price
$46.88
Change
-$0.74 (-1.55%)
Updated
May 8 closing price
Capitalization
109.66B
83 days until earnings call
Ad is loading...

AMGN vs BMY

Header iconAMGN vs BMY Comparison
Open Charts AMGN vs BMYBanner chart's image
Amgen
Price$272.05
Change-$3.79 (-1.37%)
Volume$3.62M
Capitalization151.69B
Bristol-Myers Squibb
Price$46.88
Change-$0.74 (-1.55%)
Volume$23.4M
Capitalization109.66B
AMGN vs BMY Comparison Chart
Loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMGN vs. BMY commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and BMY is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (AMGN: $272.05 vs. BMY: $46.88)
Brand notoriety: AMGN and BMY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 115% vs. BMY: 159%
Market capitalization -- AMGN: $151.69B vs. BMY: $109.66B
AMGN [@Pharmaceuticals: Major] is valued at $151.69B. BMY’s [@Pharmaceuticals: Major] market capitalization is $109.66B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 2 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s).

  • AMGN’s FA Score: 2 green, 3 red.
  • BMY’s FA Score: 2 green, 3 red.
According to our system of comparison, both AMGN and BMY are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 4 TA indicator(s) are bullish while BMY’s TA Score has 5 bullish TA indicator(s).

  • AMGN’s TA Score: 4 bullish, 7 bearish.
  • BMY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BMY is a better buy in the short-term than AMGN.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -4.13% price change this week, while BMY (@Pharmaceuticals: Major) price change was -5.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.19%. For the same industry, the average monthly price growth was +5.80%, and the average quarterly price growth was -6.59%.

Reported Earning Dates

AMGN is expected to report earnings on Aug 05, 2025.

BMY is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.19% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMGN($152B) has a higher market cap than BMY($110B). AMGN has higher P/E ratio than BMY: AMGN (22.66) vs BMY (13.73). AMGN YTD gains are higher at: 5.765 vs. BMY (-15.291). BMY has higher annual earnings (EBITDA): 19.4B vs. AMGN (14.8B). BMY has more cash in the bank: 12.3B vs. AMGN (10.9B). BMY has less debt than AMGN: BMY (41.5B) vs AMGN (64.6B). BMY has higher revenues than AMGN: BMY (45B) vs AMGN (28.2B).
AMGNBMYAMGN / BMY
Capitalization152B110B138%
EBITDA14.8B19.4B76%
Gain YTD5.765-15.291-38%
P/E Ratio22.6613.73165%
Revenue28.2B45B63%
Total Cash10.9B12.3B89%
Total Debt64.6B41.5B156%
FUNDAMENTALS RATINGS
AMGN vs BMY: Fundamental Ratings
AMGN
BMY
OUTLOOK RATING
1..100
5758
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
37100
SMR RATING
1..100
1630
PRICE GROWTH RATING
1..100
6062
P/E GROWTH RATING
1..100
9149
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (4) in the Pharmaceuticals Major industry is in the same range as AMGN (21) in the Biotechnology industry. This means that BMY’s stock grew similarly to AMGN’s over the last 12 months.

AMGN's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for BMY (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than BMY’s over the last 12 months.

AMGN's SMR Rating (16) in the Biotechnology industry is in the same range as BMY (30) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.

AMGN's Price Growth Rating (60) in the Biotechnology industry is in the same range as BMY (62) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.

BMY's P/E Growth Rating (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMGN (91) in the Biotechnology industry. This means that BMY’s stock grew somewhat faster than AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNBMY
RSI
ODDS (%)
Bullish Trend 1 day ago
53%
Bullish Trend 1 day ago
53%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
61%
Momentum
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
52%
MACD
ODDS (%)
Bearish Trend 1 day ago
51%
Bullish Trend 1 day ago
54%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 1 day ago
53%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
47%
Bearish Trend 1 day ago
50%
Advances
ODDS (%)
Bullish Trend 9 days ago
56%
Bullish Trend 9 days ago
54%
Declines
ODDS (%)
Bearish Trend 3 days ago
52%
Bearish Trend 3 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 1 day ago
61%
Aroon
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
49%
View a ticker or compare two or three
Ad is loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HPQ26.330.48
+1.86%
HP
MAX9.970.06
+0.61%
MediaAlpha
LOPE192.84-1.17
-0.60%
Grand Canyon Education
WGS56.36-0.98
-1.71%
GeneDx Holdings Corp
VHC8.10-0.15
-1.82%
VirnetX Holding Corp

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
-1.37%
PFE - AMGN
49%
Loosely correlated
+0.79%
NVS - AMGN
44%
Loosely correlated
-1.41%
ABBV - AMGN
44%
Loosely correlated
-1.33%
GSK - AMGN
43%
Loosely correlated
-0.81%
JNJ - AMGN
36%
Loosely correlated
-1.04%
More

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
-1.55%
PFE - BMY
44%
Loosely correlated
+0.79%
JNJ - BMY
39%
Loosely correlated
-1.04%
GILD - BMY
39%
Loosely correlated
-0.75%
AMGN - BMY
33%
Loosely correlated
-1.37%
RHHBY - BMY
30%
Poorly correlated
-3.03%
More